within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AX04_Difelikefalin;

model Difelikefalin
  extends Pharmacolibrary.Drugs.ATC.V.V03AX04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V03AX04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Difelikefalin is a selective kappa opioid receptor agonist, used for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. It is approved for medical use and acts peripherally with minimal crossing of the blood-brain barrier, reducing the risk of central opioid side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients undergoing hemodialysis, following intravenous administration.</p><h4>References</h4><ol><li><p>Stark, JG, et al., &amp; Menzaghi, F (2023). Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis. <i>Clinical pharmacokinetics</i> 62(9) 1231–1241. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01262-2\">10.1007/s40262-023-01262-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37369955/\">https://pubmed.ncbi.nlm.nih.gov/37369955</a></p></li><li><p>Spencer, RH, et al., &amp; Menzaghi, F (2024). Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus. <i>BMC nephrology</i> 25(1) 351–None. DOI:<a href=\"https://doi.org/10.1186/s12882-024-03790-w\">10.1186/s12882-024-03790-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39402448/\">https://pubmed.ncbi.nlm.nih.gov/39402448</a></p></li><li><p>Narita, I, et al., &amp; Gejyo, F (2022). Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial. <i>JAMA network open</i> 5(5) e2210339–None. DOI:<a href=\"https://doi.org/10.1001/jamanetworkopen.2022.10339\">10.1001/jamanetworkopen.2022.10339</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35511180/\">https://pubmed.ncbi.nlm.nih.gov/35511180</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Difelikefalin;
